Atomera Incorporated
ATOMAtomera Incorporated's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is between stages. Underneath, the last four quarters read mixed. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Atomera Incorporated trades at $5.7, between stages. That is +13.0% against its own 200-day average. It sits at 40% of a 52-week range of $2 to $11. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (3 weeks and counting).
Today the stock is between stages. At $5.7 it trades +13.0% versus its 200-day average and sits at 40% of its 52-week range ($2–$11).
Against the market, two honest reads. Cumulative: over the last 1.1 years the stock moved +19% while the S&P 500 moved +24% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (3 weeks and counting; last ahead the week of 2026-07-17) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
P/E does not price Atomera Incorporated — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. A P/E returns here the first period the bottom line turns positive.
With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read.
Atomera Incorporated reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 10 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
4-Factor Sector Score
43.8/100 — rank 29 of 29 in Semiconductor Equipment & Materials · 43% evidence confidence · provisional, ranked below fully-evidenced peers
Atomera Incorporated scores 43.8 out of 100 against the 29 companies it is compared with in Semiconductor Equipment & Materials, ranking 29. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 21.8 + 4.9 + 10 + 7.1 = 43.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Atomera Incorporated reported $0.0 B of revenue in the Mar 26 quarter. The last full year, FY25, came in at $0.0 B. The last four reported quarters add to $0.0 B. A multi-year compound rate is not shown because the annual history behind it is too short to compute one honestly.
FY25 revenue came in at $0.0 B (null on the year). The latest quarter (Mar 26) printed $0.0 B, null year on year.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
A clean operating margin is not in our numbers for Atomera Incorporated — its accounts do not report the operating-profit line this section reads, which is common for lenders and holding companies. The sections above and below carry the readings this company's filings do support.
This company's accounts do not report the operating-profit line this section reads — common for lenders and holding companies classified outside the financial bucket. The revenue and net-profit sections are the cleaner reads for Atomera Incorporated.
Why: the numbers show the operating margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Atomera Incorporated posted a net loss of $0.01 B in the Mar 26 quarter. The full FY25 year was a loss of $0.02 B. The same quarter a year earlier earned $0.0 B. 3 of the last 12 reported quarters were loss-making.
Mar 26 profit was $−0.0 B, null year on year. On the full year, FY25 printed $−0.0 B (null).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Atomera Incorporated's cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $−0.0 B of operating cash against $−0.0 B of profit. After $0.0 B of capital spending, $−0.0 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY25: operating cash of $−0.0 B against reported profit of $−0.0 B, leaving free cash of $−0.0 B after $0.0 B of capital spending.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Atomera Incorporated does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Nothing is estimated in place of the missing day-counts, so no cash-cycle chart is drawn.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Atomera Incorporated earns a ROE of −100% in FY25. That is up from a trough of −100% in FY22. Return on invested capital clears the cost of that capital by −63.8 percentage points, so growth here is not yet paying for the capital it uses.
FY25 ROE is −100%, recovered from a FY22 trough of −100% — the full ladder below shows the fall and the climb, undoctored.
The capstone test — ROIC − WACC: −48.3% − 15.5% = a −63.8 pp spread. The 15.5% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend
Atomera Incorporated pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Atomera Incorporated does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Atomera Incorporated carries total debt of $0.0 B against shareholder equity of $0.0 B as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.33 in FY21 to 0.00 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of $0.0 B against shareholder equity of $0.0 B — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.33 (FY21) to 0.00 (FY25). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
16.5% of Atomera Incorporated's tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 6.8 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 16.5% of the float is sold short, and at typical trading volumes it would take about 6.8 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Atomera Incorporated: the Z-score reads 16.86. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 16.86 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 16.86.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Teradyne, Inc.TER | 69.6/100Thin evidence · provisional58% evidence | TURNING | 24.3/35 Revenue — · PAT — · OPM change 19.3 pp 45% evidence | 18.4/25 ROCE 12.7% · OPM 36.9% 76% evidence | 10.1/20 P/E 59.9× · PEG — 15% evidence | 16.8/20 RS sector 5.5% · RS bench 40% · 1Y 275.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 24.3 + 18.4 + 10.1 + 16.8 = 69.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Applied Materials, Inc.AMAT | 68.2/100Favorable setup85% evidence | LEADER | 22.1/35 Revenue 3.3% · PAT 25.9% · OPM change 1.4 pp 95% evidence | 16.4/25 ROCE 8.9% · OPM 31.9% 76% evidence | 11.1/20 P/E 39.2× · PEG 1.32 65% evidence | 18.6/20 RS sector 7.8% · RS bench 44.6% · 1Y 195.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 16.4 + 11.1 + 18.6 = 68.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Lam Research CorporationLRCX | 63.8/100Thin evidence · provisional58% evidence | FADING | 21.9/35 Revenue — · PAT — · OPM change 1.9 pp 45% evidence | 19.4/25 ROCE 15.5% · OPM 35% 76% evidence | 9.6/20 P/E 65.8× · PEG — 15% evidence | 12.9/20 RS sector -2.8% · RS bench 30.9% · 1Y 212.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 19.4 + 9.6 + 12.9 = 63.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4ACM Research, Inc.ACMR | 60.9/100Mixed-positive evidence81% evidence | BREAKING OUT | 17.6/35 Revenue 19.7% · PAT -9% · OPM change 0.6 pp 83% evidence | 11.8/25 ROCE 2% · OPM 15.6% 76% evidence | 14.7/20 P/E 30× · PEG 0.75 65% evidence | 16.8/20 RS sector 2.7% · RS bench 38.8% · 1Y 244.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 11.8 + 14.7 + 16.8 = 60.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5ASML Holding N.V.ASML | 56.1/100Mixed-positive evidence85% evidence | FADING | 22.6/35 Revenue 9.8% · PAT 13.5% · OPM change 2.5 pp 95% evidence | 17.5/25 ROCE 11% · OPM 37.1% 76% evidence | 4.7/20 P/E 63.3× · PEG 4.28 65% evidence | 11.3/20 RS sector -15.3% · RS bench 18.8% · 1Y 137%9 of 12 weeks ahead 100% evidence |
| Exact sum: 22.6 + 17.5 + 4.7 + 11.3 = 56.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 6Kulicke and Soffa Industries, Inc.KLIC | 55.0/100Thin evidence · provisional58% evidence | FADING | 23.2/35 Revenue — · PAT — · OPM change 20 pp 45% evidence | 12.6/25 ROCE 4% · OPM 15.9% 76% evidence | 9.8/20 P/E 61.6× · PEG — 15% evidence | 9.4/20 RS sector -4.9% · RS bench 26.7% · 1Y 165%10 of 12 weeks ahead 100% evidence |
| Exact sum: 23.2 + 12.6 + 9.8 + 9.4 = 55 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7FormFactor, Inc.FORM | 54.6/100Thin evidence · provisional58% evidence | ASLEEP | 22.5/35 Revenue — · PAT — · OPM change 5.5 pp 45% evidence | 12.7/25 ROCE 5.2% · OPM 7.4% 76% evidence | 9.0/20 P/E 89.5× · PEG — 15% evidence | 10.4/20 RS sector 1.3% · RS bench 30.9% · 1Y 320.9%7 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 12.7 + 9 + 10.4 = 54.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8KLA CorporationKLAC | 54.3/100Thin evidence · provisional58% evidence | FADING | 16.4/35 Revenue — · PAT — · OPM change -1.3 pp 45% evidence | 18.2/25 ROCE 12.1% · OPM 41.2% 76% evidence | 9.2/20 P/E 82.4× · PEG — 15% evidence | 10.5/20 RS sector -15.5% · RS bench 16.9% · 1Y 113.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 16.4 + 18.2 + 9.2 + 10.5 = 54.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Cohu, Inc.COHU | 52.8/100Thin evidence · provisional58% evidence | FADING | 20.1/35 Revenue — · PAT — · OPM change 19.3 pp 45% evidence | 5.4/25 ROCE 0% · OPM -8.9% 76% evidence | 9.9/20 P/E 60× · PEG — 15% evidence | 17.4/20 RS sector 5.2% · RS bench 41.2% · 1Y 172.5%9 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 5.4 + 9.9 + 17.4 = 52.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10AXT, Inc.AXTI | 51.3/100Thin evidence · provisional58% evidence | ASLEEP | 22.1/35 Revenue — · PAT — · OPM change 47.2 pp 45% evidence | 7.0/25 ROCE 1.7% · OPM -5.9% 76% evidence | 8.5/20 P/E 3604× · PEG — 15% evidence | 13.7/20 RS sector 36.7% · RS bench 50.9% · 1Y 2950%5 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 7 + 8.5 + 13.7 = 51.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Aehr Test Systems, Inc.AEHR | 48.8/100Thin evidence · provisional58% evidence | TURNING | 15.7/35 Revenue — · PAT — · OPM change -34.9 pp 45% evidence | 5.0/25 ROCE -0.7% · OPM -41% 76% evidence | 11.5/20 P/E 12.4× · PEG — 15% evidence | 16.6/20 RS sector 65.3% · RS bench 106.2% · 1Y 503.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 5 + 11.5 + 16.6 = 48.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Amkor Technology, Inc.AMKR | 48.3/100Thin evidence · provisional58% evidence | FADING | 21.0/35 Revenue — · PAT — · OPM change 3.6 pp 45% evidence | 12.5/25 ROCE 3% · OPM 6% 76% evidence | 10.8/20 P/E 38.7× · PEG — 15% evidence | 4.0/20 RS sector -23% · RS bench 4.2% · 1Y 141.5%8 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 12.5 + 10.8 + 4 = 48.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Amtech Systems, Inc.ASYS | 48.2/100Thin evidence · provisional58% evidence | FADING | 20.5/35 Revenue -13.2% · PAT — · OPM change 211.5 pp 62% evidence | 9.3/25 ROCE 2.5% · OPM 8.8% 76% evidence | 9.3/20 P/E 68.7× · PEG — 15% evidence | 9.1/20 RS sector -11.2% · RS bench 19.9% · 1Y 259.6%8 of 12 weeks ahead 70% evidence |
| Exact sum: 20.5 + 9.3 + 9.3 + 9.1 = 48.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Ichor Holdings, Ltd.ICHR | 47.0/100Mixed-negative evidence64% evidence | FADING | 16.6/35 Revenue 7.6% · PAT — · OPM change 1.3 pp 62% evidence | 5.8/25 ROCE 0.2% · OPM 0.8% 76% evidence | 10.4/20 P/E 48.1× · PEG — 15% evidence | 14.2/20 RS sector 20.6% · RS bench 48.4% · 1Y 308.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 5.8 + 10.4 + 14.2 = 47 · Decision use: Price leads the evidence: RS versus the benchmark is 48.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 15Nova Ltd.NVMI | 46.4/100Mixed-negative evidence81% evidence | ASLEEP | 21.4/35 Revenue 21.4% · PAT 24.6% · OPM change 0.5 pp 83% evidence | 15.7/25 ROCE 5.6% · OPM 30.1% 76% evidence | 6.7/20 P/E 54.1× · PEG 2.56 65% evidence | 2.6/20 RS sector -34.6% · RS bench -7.4% · 1Y 53%4 of 12 weeks ahead 100% evidence |
| Exact sum: 21.4 + 15.7 + 6.7 + 2.6 = 46.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Photronics, Inc.PLAB | 45.4/100Mixed-negative evidence85% evidence | ASLEEP | 14.4/35 Revenue 0.5% · PAT 24.1% · OPM change -6.3 pp 95% evidence | 13.8/25 ROCE 2.6% · OPM 20.1% 76% evidence | 16.3/20 P/E 18.2× · PEG 0.43 65% evidence | 0.9/20 RS sector -36.1% · RS bench -9.2% · 1Y 61.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.4 + 13.8 + 16.3 + 0.9 = 45.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 17Ultra Clean Holdings, Inc.UCTT | 44.3/100Mixed-negative evidence64% evidence | FADING | 12.9/35 Revenue -3.2% · PAT -574.4% · OPM change -0.4 pp 62% evidence | 6.6/25 ROCE 0.7% · OPM 2.1% 76% evidence | 10.9/20 P/E 35.5× · PEG — 15% evidence | 13.9/20 RS sector 11.3% · RS bench 40.5% · 1Y 264.4%11 of 12 weeks ahead 100% evidence |
| Exact sum: 12.9 + 6.6 + 10.9 + 13.9 = 44.3 · Decision use: Price leads the evidence: RS versus the benchmark is 40.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 18Onto Innovation Inc.ONTO | 44.3/100Thin evidence · provisional56% evidence | FADING | 12.9/35 Revenue — · PAT — · OPM change -18.5 pp 39% evidence | 9.9/25 ROCE 0.7% · OPM 5.2% 76% evidence | 10.2/20 P/E 59.7× · PEG — 15% evidence | 11.3/20 RS sector -5.6% · RS bench 27.8% · 1Y 179.5%8 of 12 weeks ahead 100% evidence |
| Exact sum: 12.9 + 9.9 + 10.2 + 11.3 = 44.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Ambarella, Inc.AMBA | 44.2/100Mixed-negative evidence64% evidence | FADING | 22.3/35 Revenue 27.8% · PAT — · OPM change 10.8 pp 71% evidence | 3.5/25 ROCE -3.2% · OPM -19.3% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.4/20 RS sector -34.4% · RS bench 2.6% · 1Y 27.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 22.3 + 3.5 + 10 + 8.4 = 44.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20InTest CorporationINTT | 44.0/100Thin evidence · provisional58% evidence | ASLEEP | 19.5/35 Revenue -5.5% · PAT — · OPM change 13.6 pp 62% evidence | 8.2/25 ROCE 0.8% · OPM 2.8% 76% evidence | 8.6/20 P/E 341.3× · PEG — 15% evidence | 7.7/20 RS sector -16.9% · RS bench 13.1% · 1Y 103.8%4 of 12 weeks ahead 70% evidence |
| Exact sum: 19.5 + 8.2 + 8.6 + 7.7 = 44 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Entegris, Inc.ENTG | 42.6/100Mixed-negative evidence81% evidence | ASLEEP | 14.5/35 Revenue -0.3% · PAT -14.8% · OPM change 1.6 pp 83% evidence | 10.9/25 ROCE 1.8% · OPM 17.4% 76% evidence | 7.7/20 P/E 67× · PEG 1.93 65% evidence | 9.5/20 RS sector -19% · RS bench 14.7% · 1Y 97.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 10.9 + 7.7 + 9.5 = 42.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Camtek Ltd.CAMT | 39.3/100Mixed-negative evidence81% evidence | ASLEEP | 11.0/35 Revenue 10.6% · PAT -61.7% · OPM change -5.2 pp 83% evidence | 13.5/25 ROCE 2.7% · OPM 22.4% 76% evidence | 11.8/20 P/E 174.3× · PEG 0.8 65% evidence | 3.0/20 RS sector -29.6% · RS bench -0.7% · 1Y 82.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 11 + 13.5 + 11.8 + 3 = 39.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23IPG Photonics CorporationIPGP | 39.2/100Mixed-negative evidence74% evidence | ASLEEP | 14.8/35 Revenue 9.2% · PAT — · OPM change -3.7 pp 62% evidence | 6.8/25 ROCE -0.4% · OPM -2.9% 76% evidence | 13.0/20 P/E 166.1× · PEG 0.67 65% evidence | 4.6/20 RS sector -40.8% · RS bench -14% · 1Y 25%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 6.8 + 13 + 4.6 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Axcelis Technologies, Inc.ACLS | 38.6/100Mixed-negative evidence81% evidence | FADING | 7.8/35 Revenue -11.8% · PAT -44.1% · OPM change -11.1 pp 83% evidence | 9.8/25 ROCE 0.7% · OPM 4% 76% evidence | 12.5/20 P/E 29× · PEG 1.16 65% evidence | 8.5/20 RS sector -16% · RS bench 18.4% · 1Y 75.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 7.8 + 9.8 + 12.5 + 8.5 = 38.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Veeco Instruments Inc.VECO | 37.1/100Mixed-negative evidence81% evidence | FADING | 6.8/35 Revenue -7.8% · PAT -64.1% · OPM change -10.2 pp 83% evidence | 7.2/25 ROCE -0.2% · OPM -1.7% 76% evidence | 13.7/20 P/E 89.1× · PEG 0.65 65% evidence | 9.4/20 RS sector -8.9% · RS bench 25% · 1Y 128%9 of 12 weeks ahead 100% evidence |
| Exact sum: 6.8 + 7.2 + 13.7 + 9.4 = 37.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 26Daqo New Energy Corp.DQ | 28.0/100Thin evidence · provisional58% evidence | BASING | 9.2/35 Revenue -22.8% · PAT — · OPM change -472.4 pp 62% evidence | 4.4/25 ROCE -2.6% · OPM -564.4% 76% evidence | 11.4/20 P/E 12.5× · PEG — 15% evidence | 3.0/20 RS sector -68.5% · RS bench -48.5% · 1Y -36.8%0 of 12 weeks ahead 70% evidence |
| Exact sum: 9.2 + 4.4 + 11.4 + 3 = 28 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Trio-Tech InternationalTRT | 53.0/100Thin evidence · provisional14% evidence | 17.5/35 Revenue — · PAT — · OPM change — 0% evidence | 12.5/25 ROCE — · OPM — 0% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.0/20 RS sector 0.1% · RS bench 43.9% · 1Y 259.6%8 of 8 weeks ahead to 2026-07-10 70% evidence | |
| Exact sum: 17.5 + 12.5 + 10 + 13 = 53 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Qnity Electronics, Inc.Q | 52.2/100Thin evidence · provisional38% evidence | ASLEEP | 16.7/35 Revenue — · PAT — · OPM change -0.4 pp 45% evidence | 15.0/25 ROCE 4.2% · OPM 20.6% 76% evidence | 10.5/20 P/E 45.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —7 of 12 weeks ahead 0% evidence |
| Exact sum: 16.7 + 15 + 10.5 + 10 = 52.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Atomera Incorporatedthis pageATOM | 43.8/100Thin evidence · provisional43% evidence | FADING | 21.8/35 Revenue — · PAT — · OPM change 79084.1 pp 39% evidence | 4.9/25 ROCE -19.5% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 7.1/20 RS sector -20% · RS bench 6.9% · 1Y 60.5%8 of 12 weeks ahead 70% evidence |
| Exact sum: 21.8 + 4.9 + 10 + 7.1 = 43.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Atomera Incorporated's stock price today?
Atomera Incorporated trades at $5.7, +21.2% over the past year. The company is valued at $0.0 B. The stock sits at 40% of its 52-week range of $2–$11, +13.0% versus its 200-day average. Against the S&P 500 it has been behind on a trailing-13-week view for 3 weeks. — as of 5 August 2026.
What were Atomera Incorporated's latest quarterly results?
Atomera Incorporated reported revenue of $0.0 B and a net loss of $0.0 B for the Mar 26 quarter. Earnings per share were $−0.17. — as of 5 August 2026.
What is Atomera Incorporated's revenue?
Atomera Incorporated reported revenue of $0.0 B in the Mar 26 quarter. For the full FY25 fiscal year, revenue was $0.0 B. — as of 5 August 2026.
What is Atomera Incorporated's profit?
Atomera Incorporated earned $−0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $−0.0 B. — as of 5 August 2026.
What is Atomera Incorporated's market cap?
Atomera Incorporated's market capitalisation is $0.0 B at a stock price of $5.7. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
Does Atomera Incorporated pay a dividend?
No — Atomera Incorporated has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
How is Atomera Incorporated performing?
Atomera Incorporated's latest readings are below. Against the S&P 500 it has been behind on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
Is Atomera Incorporated beating the market?
Not lately — on a trailing-13-week view Atomera Incorporated is currently behind the S&P 500 (3 weeks and counting; last ahead the week of 2026-07-17), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.1 years the stock moved +19% against the S&P 500's +24% — behind the index over the full window. — as of 5 August 2026.
Will Atomera Incorporated's stock price go up?
This page publishes no price forecast for Atomera Incorporated. What it measures instead: the stock price is $5.7. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against Atomera Incorporated?
Yes — short interest is 16.5% of Atomera Incorporated's tradable float, about 6.8 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does Atomera Incorporated have too much debt?
No — Atomera Incorporated's debt-to-equity is 0.03. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 5 August 2026.
What is Atomera Incorporated's capex?
Atomera Incorporated spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.
What is Atomera Incorporated's cash flow?
Atomera Incorporated generated $−0.0 B of operating cash flow in FY25 and $−0.0 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $−0.0 B, so operating cash ran ahead of profit. — as of 5 August 2026.
How financially safe is Atomera Incorporated?
On the balance sheet, the Z-score reads 16.86 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
What could break the Atomera Incorporated story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Atomera Incorporated a stock worth studying right now?
This is not investment advice. The machine read: Atomera Incorporated's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.